FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1636-1637 November 29, 2001 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Brown, B. G. Related Article by Schnyder, G. PubMed Citation

Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies that use the end points of acute coronary syndromes and death provide direct information on the effects of various therapies but require large samples and prolonged periods of study. Since the risk of coronary events is related to the progression of coronary lesions,¹ a highly relevant clinical end point is the attenuation of plaque formation. Studies using coronary angiography . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bruckert, E. (2005). Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets. Eur Heart J Suppl 7: L16-L20 [Abstract] [Full Text]  
• (2002). Statin plus Niacin Benefits CAD Patients with Low HDL. Journal Watch Cardiology 2002: 1-1 [Full Text]